Manhattan Scientifics Announces Early Results from Cancer Company

March 17, 2022

Click here to view the printer friendly version of this press release

Manhattan Scientifics Inc., announces positive early results from Imagion Biosystems Cancer Diagnostic human study. 

Imagion Biosystems Ltd. (IBX.AX) shares were up 46% trading 71 million shares.

Manhattan Scientifics Inc., initially funded and is the current owner of more than 50 million shares of Imagion Biosystems Ltd.

About Manhattan Scientifics

Manhattan Scientifics Inc. ( is focused on commercialization of disruptive technologies in the nano medicine space.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.